Previous 10 | Next 10 |
RESTORE Consortium, of which Pluristem is a leading member, is competing for up to a €1 billion award by the European Commission Winner announcement is expected in May 2020 HAIFA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE...
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantation Data from 1 st and 2 nd cohorts of hematological study showed PLX-R18 was safe and well tolerated and led to in...
Noteworthy events during the week of September 15 - 21 for healthcare investors. More news on: CRISPR Therapeutics AG, Pluristem Therapeutics Inc., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader (KOL) call regarding its hemat...
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key Opinion Leader (KOL) call on its h...
Nano cap Pluristem Therapeutics (NASDAQ: PSTI ) is up 2% premarket on modestly higher volume in response to preclinical data on cell therapy PLX-R18 as a potential preventative countermeasure against acute radiation syndrome administered prior to exposure. More news on: Pluri...
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineages Data is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (...
Noteworthy events during the week of July 28 - August 3 for healthcare investors. More news on: Pluristem Therapeutics Inc., Mylan N.V., Intra-Cellular Therapies, Inc., Healthcare stocks news, , Read more ...
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Ya...
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved a 1-for-10 reverse split ...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...